These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 33843664)
1. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma. Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664 [TBL] [Abstract][Full Text] [Related]
2. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029 [TBL] [Abstract][Full Text] [Related]
3. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082 [TBL] [Abstract][Full Text] [Related]
4. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528 [TBL] [Abstract][Full Text] [Related]
5. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597 [TBL] [Abstract][Full Text] [Related]
6. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265 [TBL] [Abstract][Full Text] [Related]
7. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706 [TBL] [Abstract][Full Text] [Related]
8. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071 [TBL] [Abstract][Full Text] [Related]
9. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857 [TBL] [Abstract][Full Text] [Related]
12. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637 [TBL] [Abstract][Full Text] [Related]
13. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy. Liu X; Zhu X; Qi X; Meng X; Xu K Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204 [TBL] [Abstract][Full Text] [Related]
15. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922 [TBL] [Abstract][Full Text] [Related]
16. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921 [TBL] [Abstract][Full Text] [Related]
17. Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system. Jin M; Shi C; Li T; Wu Y; Hu C; Huang G Biomed Pharmacother; 2020 Sep; 129():110282. PubMed ID: 32531676 [TBL] [Abstract][Full Text] [Related]
18. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption. Lai Y; Lu N; Luo S; Wang H; Zhang P J Med Chem; 2022 Oct; 65(19):13041-13051. PubMed ID: 36134739 [TBL] [Abstract][Full Text] [Related]
19. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib. Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316 [TBL] [Abstract][Full Text] [Related]
20. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]